Combining Sodium Hyaluronate and Polyvinylpyrrolidone Therapies for the Rabbit Cornea: A New Approach to Relief of the Human Dry Eye Syndrome

References

• Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000;19:644–649
   PubMed Web of Science ®Google Scholar
• The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocular Surf 2007;5:75–92
   Google Scholar
• Lemp MA. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J 1995;21:221–232
   PubMedGoogle Scholar
• Shimmura S, Ono M, Shinozaki K, Toda I, Takamura E, Mashima Y, et al. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol 1995;79:1007–1011
   PubMed Web of Science ®Google Scholar
• McDonald CC, Kaye SB, Figueiredo FC, Macintosh G, Lockett C. A randomized, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond) 2002;16:601–607
   PubMed Web of Science ®Google Scholar
• Vogel R, Crockett RS, Oden N, Laliberte TW, Molina L. Sodium Hyaluronate Ophthalmic Solution Study Group. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol 2010;149:594–601
   PubMed Web of Science ®Google Scholar
• Gobbels M, Spitznas M. Effects of artificial tears on corneal epithelial permeability in dry eyes. Graefes Arch Clin Exp Ophthalmol 1991;229:345–349
   PubMed Web of Science ®Google Scholar
• Buchsel PC. Polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions. Expert Opin Drug Metab Toxicol 2008;4:1449–1454
   PubMed Web of Science ®Google Scholar
• Fujihara T, Nagano T, Nakamura M, Shirasawa E. Establishment of a rabbit short-term dry eye model. J Ocul Pharmacol 1995;11:503–508
   Google Scholar
• Francois J, Maudgal PC, Victoriatroncoso V. Experimental keratitis sicca: the corneal epithelium at the transmission and scanning electron microscope. Ophthalmic Res 1976;8:414–424
   Web of Science ®Google Scholar
• Gilbard JP, Hanninen LA, Rothman RC, Kenyon, KR. Lacrimal gland, cornea, and tear film in the NZB/NZW F1 hybrid mouse. Curr Eye Res 1987;6:1237–1248
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ishimaru N, Yanagi K, Haneji N, Saito I, Hayashi Y. High incidence of autoimmune dacryoadenitis in male non-obese diabetic (NOD) mice depending on sex steroid. Clin Exp Immunol 1997;109:555–561
   PubMed Web of Science ®Google Scholar
• Van Blokland SC, Versnel MA. Pathogenesis of Sjogren's syndrome: characteristics of different mouse model for autoimmune exocrinopathy. Clin Immunol 2002;103:111–124
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Sullivan, DB, Ullman MD, Rocha EM, Krenzer KL, Cermak JM, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 2000;41:3732–3742
   PubMed Web of Science ®Google Scholar
• Dursun D, Wang M, Monroy D, Li DQ, Lokeshwar BL, Stern ME, et al. A mouse model of kerato-conjunctivitis sicca. Invest Ophthalmol Vis Sci 2002;43:632–638
   PubMed Web of Science ®Google Scholar
• Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci 2005;46:2766–2771
   PubMed Web of Science ®Google Scholar
• Chen W, Zhang X, Zhang J, Chen J, Wang S, Wang Q, Qu J. A murine model of dry eye induced by an intelligently controlled environmental system. Invest Ophthalmol Vis Sci 2008;49:1386–1391
   PubMed Web of Science ®Google Scholar
• Barabino S, Dana MR. Animal models of dry eye: a critical assessment of opportunities and limitations. Invest Ophthalmol Vis Sci 2004;45:1641–1646
   PubMed Web of Science ®Google Scholar
• Xiong C, Chen D, Liu J, Liu B, Li N, Zhou Y, et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci 2008;49:1850–1856
   PubMed Web of Science ®Google Scholar
• Yu F, Liu X, Zhong Y, Guo X, Li M, Mao Z, et al. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study. Invest Ophthalmol Vis Sci 2013;54:3385–3393
   PubMed Web of Science ®Google Scholar
• Papas EB. Key factors in the subjective and objective assessment of conjunctival erythema. Invest Ophthalmol Vis Sci 2000; 41:687–691
   PubMed Web of Science ®Google Scholar
• Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640–650
   PubMed Web of Science ®Google Scholar
• NDA 22–358 FDA Advisory Committee Briefing Document. Sodium hyaluronate ophthalmic solution 0.18% for the treatment of the signs and symptoms of dry eye disease. Chapel Hill, NC: FDA; 2009. pp 1–115
   Google Scholar
• Folttmann H, Quadir A. Polyvinylpyrrolidone (PVP) – one of the most widely used excipients in pharmaceuticals: an overview. Drug Deliv Technol 2008;8:22–27
   Google Scholar
• Saraswati B, Balaji A, Umashanker MS. Polymers in mucoadhesive drug delivery systems-latest updates. Int J Pharmaceut Sci 2013;5:423–430
   Google Scholar
• Haaf F, Sanner A, Straub F. Polymers of N-vinylpyrrolidone: synthesis, characterization and uses. Polymer J 1985;17:143–152
   Web of Science ®Google Scholar
• Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881–1884
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233–236
   PubMedGoogle Scholar
• Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol 1984;102:1049–1051
   PubMed Web of Science ®Google Scholar
• Ralph RA. Conjunctival goblet cell density in normal subjects and in dry eye syndromes. Invest Ophthalmol Vis Sci 1975;14:299–302
   Web of Science ®Google Scholar
• Lapalus P, Ettaiche M, Fredj-Reygrobellet D, Jambou D, Elena PP. Cytotoxicity studies in ophthalmology. Lens Eye Toxic Res 1990;7:231–242
   PubMedGoogle Scholar
• Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337–342
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, de Paiva CS, Tong L, Luo L, Stern ME, Li DQ. Stress-activated protein kinase signaling pathways in dry eye and ocular surface disease. Ocul Surf 2005;3:S154–S157
   PubMed Web of Science ®Google Scholar